GlassScriptPhysician profile
Renu R Shishodia
NPI 1386785962
$14,440.58
in general payments reported to CMS, 2019-2025
33 companies · $2,772 in 2025
The $2,772 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $1,562 · 2021: $2,313 · 2022: $2,927 · 2023: $1,917 · 2024: $2,238 · 2025: $2,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,855 · Education: $71.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,854.79 |
| Education | $71.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $3,359.60 | 2019-2022 | |
| Abbvie INC. | $1,282.68 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $947.87 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $924.20 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $924.09 | 2020-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $884.68 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $865.15 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $808.50 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $766.56 | 2019-2025 | Trintellix |
| Alkermes, INC. | $664.27 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $549.06 | 2020-2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $370.32 | 2019-2024 | Jornay Pm |
| Corium, LLC | $284.50 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $271.78 | 2021-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $185.62 | 2019-2025 | Rexulti |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $182.84 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $174.74 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $125.26 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $116.27 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $105.76 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $99.37 | 2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Eisai INC. | $96.80 | 2020-2021 | |
| Allergan, INC. | $92.85 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $72.59 | 2019 | |
| Almatica Pharma LLC | $63.03 | 2022-2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $43.46 | 2021-2023 | Lamotrigine, Subvenite |
| Biogen, INC. | $40.02 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $31.47 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $29.77 | 2023 | Latuda |
| Adlon Therapeutics L.P. | $27.23 | 2020-2021 | |
| Tms Neurohealth Centers INC. | $21.37 | 2025 | Tms Neurohealth Centers INC. |
| Noven Pharmaceuticals, INC. | $15.75 | 2021 | |
| Bausch Health US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renu Shishodia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.